Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis gains exclusive rights to PTK 0796

Novartis gains exclusive rights to PTK 0796

8th October 2009

Novartis revealed this week that it has been granted the exclusive worldwide rights to the oral broad-spectrum antibiotic PTK 0796.

The drug, which is currently undergoing phase III testing, is potentially the first once-daily broad-spectrum antibiotic that can be given by intravenous infusion or oral tablet to treat a wide variety of life-threatening conditions.

These include infections brought about by bacteria such as methicillin-resistant Staphylococcus aureus and the multi-drug resistant Streptococcus pneumoniae.

Joe Jimenez, chief executive of Novartis’ pharmaceuticals division, commented: “It will potentially benefit patients by offering a flexible and highly-effective approach to the treatment of a number of critical infections and should form an important addition to our growing portfolio.”

Earlier this week, Novartis division Sandoz announced the launch of its human growth hormone somatropin, following the drug’s approval in June 2009 for the treatment of growth hormone deficiency in children.

It can also be used to treat growth disturbance associated with Turner’s syndrome or chronic renal insufficiency.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.